Help personalize your patients’ cancer treatment

Optimizing colorectal cancer care with genetic testing

• Genetic testing is underutilized in patients with colorectal cancer despite insurance coverage.⁶
• There are more than one million colorectal cancer survivors in the United States, and the majority haven’t undergone hereditary cancer genetic testing.^7,8
• 1 in 7 patients with colorectal cancer have a disease-causing gene variant that may impact medical management ^1,6,9

Hereditary cancer genetic testing can optimize patient care and help:

• Assess future risk of colorectal cancer and other cancer types ^{1,6 10}
• Inform starting age and frequency of screenings such as colonoscopies ^1,6,10
• Inform surgical options for patients with Lynch syndrome ^{1, 6}
• Inform treatment options for patients with advanced disease ¹
• Understand potential cancer risks for family members ¹

Start an order

Guiding ovarian cancer care with genetic testing

• Hereditary genetic test results are important for identifying patients who need targeted therapy. Targeted treatments like PARP inhibitors (sometimes preceded by platinum-based chemotherapy) can improve progression-free survival outcomes in both frontline and recurrent settings.¹¹
• 1 in 5 patients with ovarian cancer have a gene variant that increases cancer risk.¹
• Over 30% of women with disease-causing gene variants had no family history of breast or ovarian cancer, highlighting the importance of hereditary cancer genetic testing for all patients with ovarian cancer. ¹²

Start an order

Revealing genetic insights for pancreatic cancer care

• Patients with pancreatic cancer could benefit from hereditary cancer genetic testing for customized clinical management recommendations^13,14
• 1 in 7 patients with pancreatic cancer may have an inherited gene variant. ^1,15,16
• 78% of patients with pancreatic cancer who had disease-causing gene variants were potentially eligible for precision therapies or clinical trials.¹⁵
  
  Start an order

Informing genetic insights for prostate cancer

• High-risk genetic variants, such as those in the BRCA2 gene, are associated with more biologically aggressive prostate cancer.^18-20 In metastatic cases, survival among men with a BRCA1 or BRCA2 variant is half that of men with no genetic variant.¹⁹ Early detection may give your patients a better chance at improved outcomes.^19,21,22
• 1 in 7 patients with prostate cancer have a disease-causing gene variant. ^1,17,23
• As many as 70% of men with advanced or metastatic prostate cancer who had an actionable disease-causing hereditary cancer variant didn’t qualify for genetic testing based on family history.²⁴

Start an order